Pharmaceutical giant Merck has announced a definitive agreement to acquire Terns Pharmaceuticals, a clinical-stage oncology company, in a deal valued at approximately $6.7 billion. This strategic acquisition is designed to bolster Merck's cancer treatment portfolio, particularly as it prepares for the patent expiration of its blockbuster drug, Keytruda. The deal centers on Terns' promising lead candidate for treating chronic myeloid leukemia, signaling a significant expansion of Merck's presence in hematology.
Strategic Expansion in Oncology
Merck's acquisition of Terns is a proactive measure to diversify its revenue streams and strengthen its long-term position in the oncology market. The impending patent expiration of Keytruda, a major contributor to Merck's revenue, has created a strategic imperative to invest in new, innovative therapies. By acquiring Terns, Merck gains a high-potential asset in hematology, a key area for future growth in cancer treatment.
A Closer Look at TERN-701
The centerpiece of the acquisition is TERN-701, an investigational oral drug designed to treat certain patients with chronic myeloid leukemia (CML). This novel allosteric BCR::ABL1 tyrosine kinase inhibitor is currently in a Phase 1/2 clinical trial for patients who have previously failed other treatments. The U.S. Food and Drug Administration has already granted Orphan Drug Designation to TERN-701, underscoring its potential to address a significant unmet medical need.
Early clinical trial results for TERN-701 have demonstrated promising activity, with notable molecular response rates observed in patients with a high disease burden. The treatment has also shown a favorable safety profile, with most adverse events reported as low-grade and a low rate of discontinuations. This combination of efficacy and tolerability positions TERN-701 as a potentially best-in-class candidate for CML therapy.
Financial and Transactional Details
Under the terms of the agreement, a Merck subsidiary will initiate a tender offer to acquire all outstanding shares of Terns for $53.00 per share in cash. This price represents a substantial premium of 42% over the company's 90-day volume-weighted average stock price. The total equity value of the transaction is approximately $6.7 billion, reflecting the significant value attributed to Terns' clinical pipeline.
The boards of directors for both Merck and Terns have unanimously approved the transaction, which is expected to close in the second quarter of 2026. The deal is subject to customary closing conditions, including the tender of a majority of Terns' outstanding shares and regulatory clearance. Merck anticipates recording a charge of approximately $5.8 billion, or $2.35 per share, related to the acquisition.
Leadership Perspectives and Future Outlook
Leaders from both organizations have voiced strong support for the merger, highlighting its synergistic potential for advancing cancer care. Robert M. Davis, chairman and CEO of Merck, stated that the acquisition builds on the company's growing presence in hematology and strengthens its overall oncology franchise. This move aligns with Merck's strategy to broaden its portfolio into new and impactful therapeutic areas.
Terns' CEO, Amy Burroughs, remarked that the partnership will leverage Merck's deep expertise and significant resources to accelerate the development of TERN-701. She expressed immense pride in the Terns team for their commitment to developing high-impact medicines for patients living with CML. The collaboration is poised to advance a promising therapy for those who need it most.
The acquisition of Terns Pharmaceuticals by Merck represents a pivotal and forward-looking investment to secure its leadership in oncology. By integrating TERN-701 into its pipeline, Merck not only addresses the future challenge of Keytruda's patent expiration but also reinforces its commitment to innovative cancer research. This strategic transaction is set to create significant value for both companies while holding the promise of delivering a new, effective treatment for patients with chronic myeloid leukemia.